NO175149C - Analogifremgangsmåte for fremstilling av terapeutisk aktive, eventuelt ddiksyrer og -estere - Google Patents

Analogifremgangsmåte for fremstilling av terapeutisk aktive, eventuelt ddiksyrer og -estere

Info

Publication number
NO175149C
NO175149C NO891523A NO891523A NO175149C NO 175149 C NO175149 C NO 175149C NO 891523 A NO891523 A NO 891523A NO 891523 A NO891523 A NO 891523A NO 175149 C NO175149 C NO 175149C
Authority
NO
Norway
Prior art keywords
esters
preparation
therapeutically active
acetic acids
analogous process
Prior art date
Application number
NO891523A
Other languages
English (en)
Other versions
NO891523D0 (no
NO175149B (no
NO891523L (no
Inventor
Klaus Mohrs
Siegfried Raddatz
Romanis Fruchtmann
Christian Kohlsdorfer
Reiner Muller-Peddinghaus
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO891523D0 publication Critical patent/NO891523D0/no
Publication of NO891523L publication Critical patent/NO891523L/no
Publication of NO175149B publication Critical patent/NO175149B/no
Publication of NO175149C publication Critical patent/NO175149C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO891523A 1988-04-29 1989-04-13 Analogifremgangsmåte for fremstilling av terapeutisk aktive, eventuelt ddiksyrer og -estere NO175149C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3814504A DE3814504A1 (de) 1988-04-29 1988-04-29 (alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln

Publications (4)

Publication Number Publication Date
NO891523D0 NO891523D0 (no) 1989-04-13
NO891523L NO891523L (no) 1989-10-30
NO175149B NO175149B (no) 1994-05-30
NO175149C true NO175149C (no) 1994-09-07

Family

ID=6353182

Family Applications (1)

Application Number Title Priority Date Filing Date
NO891523A NO175149C (no) 1988-04-29 1989-04-13 Analogifremgangsmåte for fremstilling av terapeutisk aktive, eventuelt ddiksyrer og -estere

Country Status (20)

Country Link
US (1) US4929626A (no)
EP (1) EP0339416B1 (no)
JP (1) JPH01313466A (no)
KR (1) KR900016136A (no)
CN (1) CN1027068C (no)
AT (1) ATE89819T1 (no)
AU (1) AU614358B2 (no)
CA (1) CA1333803C (no)
DD (1) DD283811A5 (no)
DE (2) DE3814504A1 (no)
DK (1) DK168009B1 (no)
ES (1) ES2054919T3 (no)
FI (1) FI91855C (no)
HU (1) HU205079B (no)
IE (1) IE62888B1 (no)
IL (1) IL90052A (no)
NO (1) NO175149C (no)
NZ (1) NZ228899A (no)
PT (1) PT90382B (no)
ZA (1) ZA893171B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3632329A1 (de) * 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
GB8728051D0 (en) * 1987-12-01 1988-01-06 Leo Pharm Prod Ltd Chemical compounds
DE3900261A1 (de) * 1988-05-31 1989-12-07 Bayer Ag Substituierte 4-(chinolin-2-yl-methoxy) phenyl-essigsaeure-derivate
US5232916A (en) * 1988-06-27 1993-08-03 Merck Frosst Canada, Inc. Quinoline ether alkanoic acids
US5102881A (en) * 1988-06-27 1992-04-07 Merck Frosst Canada, Inc. Quinoline ether alkanoic acids
US5194438A (en) * 1988-07-15 1993-03-16 Basf Aktiengesellschaft α-arylacrylates substituted by a trifluoromethylpyrimidinyloxy radical, fungicidal compositions and methods
DE3927931A1 (de) * 1989-08-24 1991-02-28 Bayer Ag Disubstituierte (chinolin-2-yl-methoxy)phenylessigsaeure-derivate
DE3927930A1 (de) * 1989-08-24 1991-02-28 Bayer Ag Cyclisch substituierte (chinolin-2-yl-methoxy)phenyl-essig-saeure-derivate
US5021576A (en) * 1989-10-27 1991-06-04 American Home Products Corporation 2-Anilino phenylacetic acid derivatives
US5071988A (en) * 1989-10-27 1991-12-10 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives
US5008283A (en) * 1990-03-19 1991-04-16 Pfizer Inc. Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
US5006547A (en) * 1990-03-19 1991-04-09 Pfizer Inc. Tenidap as an inhibitor of the release of elastase by neutrophils
US5204329A (en) * 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5254581A (en) * 1990-06-21 1993-10-19 Imperial Chemical Industries Plc Pyran derivatives and their use as inhibitors of 5-lipoxygenase
US4996214A (en) * 1990-06-28 1991-02-26 Smithkline Beecham Corporation Quinolinyl substituted phenyl/thioalkanoic acid substituted propionic acids and leucotriene antagonist use thereof
US5221678A (en) * 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
US5187180A (en) * 1990-07-26 1993-02-16 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
US5266568A (en) * 1990-10-12 1993-11-30 Merck Frosst Canada, Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
US5856322A (en) * 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
DE4226649A1 (de) * 1992-08-12 1994-02-17 Bayer Ag Neue isobutylsubstituierte Methansulfonyl-chinolylmethoxyphenyl-cycloalkylessigsäureaminole
DE4105551A1 (de) * 1991-02-22 1992-08-27 Bayer Ag 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE4139751A1 (de) * 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Thiazolyl substituierte chinolylmethoxyphenylessigsaeurederivate
US5304563A (en) * 1991-02-22 1994-04-19 Bayer Aktiengesellschaft 2-substituted quinolines, and their use in medicaments
DE4112533A1 (de) * 1991-04-17 1992-10-22 Bayer Ag Verfahren zur herstellung von enantiomerenreinen substituierten (chinolin-2-yl-methoxy)phenyl-essigsaeuren
EP0540165A1 (en) * 1991-10-03 1993-05-05 Zeneca Limited Alkanoic acid derivatives
DE4139750A1 (de) * 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Chinolylmethoxyphenylessigsaeure-acylamide und -harnstoffe
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
DE4219765A1 (de) * 1992-06-17 1993-12-23 Bayer Ag Substituierte (Benzothiazolyl- und Chinoxalyl-methoxy)phenylessigsäurederivate
DE4226519A1 (de) * 1992-08-11 1994-02-17 Bayer Ag 3-Substituierte Chinolylmethoxy-phenylessigsäurederivate
ES2061406B1 (es) * 1993-05-07 1995-06-01 Uriach & Cia Sa J Nuevos derivados de la 2-(quinolina) con actividad farmacologica.
DE4443892A1 (de) * 1994-12-09 1996-06-13 Bayer Ag 4-(Chinolin-2-yl-methoxy)-phenyl-essigsäurederivate
DE4443891A1 (de) 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
EP2086531A4 (en) 2006-11-30 2009-09-30 Amira Pharmaceuticals Inc COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS
ES2878405T3 (es) 2014-02-04 2021-11-18 Bioscience Pharma Partners Llc Uso de inhibidores de flap para reducir la lesión mediada por neuroinflamación en el sistema nervioso central

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56702B1 (en) * 1982-12-01 1991-11-06 Usv Pharma Corp Antiinflammatory antiallergic compounds
NZ213986A (en) * 1984-10-30 1989-07-27 Usv Pharma Corp Heterocyclic or aromatic compounds, and pharmaceutical compositions containing such
JPH0729952B2 (ja) * 1984-10-30 1995-04-05 ユ−エスヴイ− フア−マシユ−テイカル コ−ポレ−シヨン 抗炎症及び抗アレルギ−化合物
US4642347A (en) * 1985-05-21 1987-02-10 American Home Products Corporation 3(2-quinolinylalkoxy)phenols
US4661499A (en) * 1985-06-18 1987-04-28 Merck Frosst Canada, Inc. 2-[(substituted)-phenoxymethyl]quinolines

Also Published As

Publication number Publication date
CN1027068C (zh) 1994-12-21
CN1045777A (zh) 1990-10-03
DE58904459D1 (de) 1993-07-01
NO891523D0 (no) 1989-04-13
HUT50779A (en) 1990-03-28
IL90052A0 (en) 1989-12-15
DK208789D0 (da) 1989-04-28
DE3814504A1 (de) 1989-11-09
FI91855B (fi) 1994-05-13
PT90382B (pt) 1994-09-30
FI892016A0 (fi) 1989-04-27
ZA893171B (en) 1989-12-27
PT90382A (pt) 1989-11-10
IE62888B1 (en) 1995-03-08
EP0339416A1 (de) 1989-11-02
IL90052A (en) 1993-07-08
JPH01313466A (ja) 1989-12-18
DD283811A5 (de) 1990-10-24
US4929626A (en) 1990-05-29
KR900016136A (ko) 1990-11-12
FI892016A (fi) 1989-10-30
CA1333803C (en) 1995-01-03
NZ228899A (en) 1991-06-25
HU205079B (en) 1992-03-30
AU3385289A (en) 1989-11-02
DK208789A (da) 1989-10-30
AU614358B2 (en) 1991-08-29
NO175149B (no) 1994-05-30
FI91855C (fi) 1994-08-25
NO891523L (no) 1989-10-30
ES2054919T3 (es) 1994-08-16
IE891402L (en) 1989-10-29
DK168009B1 (da) 1994-01-17
EP0339416B1 (de) 1993-05-26
ATE89819T1 (de) 1993-06-15

Similar Documents

Publication Publication Date Title
NO175149C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive, eventuelt ddiksyrer og -estere
FI892603A0 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten 4-(kinolin-2-yylimetoksi)fenyylietikkahappojohdannaisten valmistamiseksi
SE8101064L (sv) Topiska farmaceutiska preparat innehallande salter av alkankarbonsyror samt nya karbonsyrasalter och forfarande for framstellning derav
NO862734L (no) Fremgangsmaate for fremstilling av hyaluronsyreestere.
DK0414078T3 (da) Disubstituerede (quinolin-2-yl-methoxy)phenyleddikesyrederivater
MY108459A (en) 2-substituted quinolines, processes for their preparation and their use in medicaments
DE59007437D1 (de) Cyclisch substituierte (Chinolin-2-yl-methoxy)phenyl-essigsäure-Derivate.
DE68901105D1 (de) Alkensaeurederivate.
FI860816A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten polyprenyyliyhdisteiden valmistamiseksi
NO942531L (no) Fremgangsmåte for fremstilling av 3-acylöstratriener og acylbenzener
NO150878C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 1-nafthyl-eddiksyrederivater
ES481296A1 (es) Un procedimiento para la preparacion de esteres de deriva- dos del acido aminolo-piran-4-ona-2-carboxilico.
AU7661887A (en) Pharmaceutical adhesive films comprising quinolone carboxylic acid derivatives
AU3471589A (en) Novel 6-phenoxymethyl-4-hydroxytetrahydropyran-2-ones and 6-thiophenoxymethyl-4-hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acid derivatives, salts and esters, processes for the preparation of these compounds their use as pharmaceuticals
NO863005D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,4,5,6,7,8-heksahydro-2-alkyl-4-aryl-5-okso-1,7-naftyridin-3-karboksylsyreesterderivater.
NO147747C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 1-oxo-5-indanyloxy-eddiksyrer, og salter derav med baser
PH17112A (en) Esters of arylpropionic acids endowed with an antiinflammatory activity,process for their preparations,and related pharmaceutical composition